Plant lactobacillus and application thereof
By screening out P. planta M111 with blood sugar-lowering and antibacterial functions, the problems of blood sugar control and food preservation in diabetic patients were solved, and effective inhibition of α-amylase, α-glucosidase and pathogenic bacteria were achieved. Provides a safe and green method of food preservation.
Patent Information
- Application Number
- CN202411027005.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
The blood sugar levels of diabetic patients are difficult to control. Traditional preservatives pose a threat to food quality and safety, and lack safe, green and efficient preservatives.
Screening and providing a plant-based P. lactobacillus M111 with blood glucose and antibacterial functions, prepare compositions for food and health products by fermentation treatment, inhibit α-amylase and α-glucosidase activities, and cause disease Bacteria have an inhibitory effect.
M111 of Plantella Lactobacillus significantly reduced blood sugar levels, with an inhibition rate of 71.44% and 62.14%, which has a significant inhibitory effect on a variety of pathogenic bacteria, tolerate gastric and pancreatic juice environments, and is sensitive to common antibiotics. It is suitable for the development of lowering blood sugar and inhibiting blood sugar. Fungal food.
Smart Images

Figure BDA0004968831390000041 
Figure BDA0004968831390000061 
Figure BDA0004968831390000071
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and particularly relates to Lactobacillus plantarum M111 and applications thereof. Background Art
[0002] Changes in modern diet and lifestyle have led to a rapid increase in the number of diabetes patients in my country. Diabetes is a metabolic disorder characterized by sustained increases in blood sugar, with type 2 diabetes being the most common. α-amylase and α-glucosidase in diabetic patients are the main reasons for their high blood sugar levels. Lactic acid bacteria regulate the activity of related enzymes in the body, control the absorption of glucose and the decomposition of carbohydrates, such as regulating α-glucosidase and α-amylase to slow down the absorption of sugars, thereby reducing blood sugar concentration and regulating the body's blood sugar level.
[0003] During food manufacturing and storage, contamination by pathogenic bacteria affects food quality and safety, causing serious harm to human health. Although the traditional method of adding chemical preservatives to extend the shelf life of food has made considerable progress, with the increasing demand for "clean label" food, it is of great significance to find safe, green and efficient preservatives to replace chemical derivatives. Lactic acid bacteria produce a large number of antibacterial metabolites during the culture process, such as organic acids, fatty acids, acetoin, hydrogen peroxide, protein compounds, phenyllactic acid, bacteriocins and hydrogen peroxide. These substances can exert antibacterial effects alone or synergistically in different systems without affecting the sensory properties of food and human health.
[0004] In order to solve the above problems, the applicant is committed to screening out lactic acid bacteria with high α-glucosidase inhibitory activity and antibacterial activity, and broadening the application of lactic acid bacteria in the fields of hypoglycemic and antibacterial. Summary of the invention
[0005] In view of the above problems, the present invention provides a strain of Lactobacillus plantarum M111 with hypoglycemic and antibacterial functions. Lactobacillus plantarum M111 (Lactiplantibacillus plantarum M111) was deposited in the General Microbiology Center of China National Committee for the Preservation of Microorganisms on May 15, 2024, with a preservation address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and a preservation number of CGMCCNO.30629.
[0006] The present invention provides a composition comprising the Lactobacillus plantarum M111 as described above.
[0007] In one embodiment, the composition includes one of a microbial preparation, a food, a health product, and a medicine.
[0008] In one embodiment, in the composition, the number of Lactobacillus plantarum M111 is ≥ 1×10 8 CFU / mL or ≥1×10 8 CFU / g.
[0009] In one embodiment, the functional products include food, medicine, and health products.
[0010] In one embodiment, the product comprises at least one of the following functions:
[0011] (1) Inhibit α-amylase activity;
[0012] (2) Inhibit α-glucosidase activity;
[0013] (3) Inhibit five foodborne pathogens, including Escherichia coli and Staphylococcus aureus;
[0014] (4) showed sensitivity to 14 antibiotics including neomycin;
[0015] (5) It has excellent tolerance to gastric and pancreatic juices.
[0016] The present invention has the following beneficial effects:
[0017] (1) The present invention provides a strain of Lactobacillus plantarum M111 with excellent in vitro hypoglycemic and antibacterial properties, which has excellent inhibitory effects on α-amylase and α-glucosidase, and the fermentation supernatant has a good inhibitory effect on α-amylase and α-glucosidase, with inhibition rates reaching 71.44% and 62.14% respectively. It has an inhibitory effect on five foodborne pathogens such as Escherichia coli and Staphylococcus aureus, among which the antibacterial intensity against Streptococcus mutans is the greatest, and the diameter of the inhibition zone exceeds 20 mm, reaching 20.29 mm. In addition, the strain has excellent tolerance to gastric and pancreatic juice, and has extremely high tolerance to simulated artificial gastric juice of pH 3.0 and pH 2.5. The tolerance to pH 3.0 and pH 2.5 for the initial 1h reached 99.32% and 98.53%, respectively; and it has good tolerance in the environment of simulated artificial pancreatic juice pH 7.5 and pH 8.0, and the survival rate reached 97.85% and 97.45% after 3h of culture, and still reached 96.80% and 95.80% after 6h of culture, both exceeding 95%. In addition, Lactobacillus plantarum M111 is sensitive to 14 common antibiotics. Lactobacillus plantarum M111 is obtained from daily food fresh milk through natural fermentation. It is a natural strain with strong safety. It can provide a new source of probiotics for the development of blood sugar-lowering products and inhibition of pathogenic bacteria in food, and has broad application prospects.
[0018] (2) The strain of the present invention can be made of various plants (such as fruits, Chinese herbal medicines, cereals, etc.) as raw materials, matched with various ingredients, inoculated with plant lactobacillus M111 for fermentation treatment to prepare a fermented product, which can be used to prepare products with hypoglycemic and weight loss functions. Among them, the fermentation raw materials can be various plant fermentation raw materials used conventionally, and the auxiliary materials can also adopt existing conventional auxiliary materials, including but not limited to the above-mentioned scheme selection. The fermented product is not limited to being used for preparing fermented foods, and can also be products such as health products and medicines. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is the colony morphology of Lactobacillus plantarum M111.
[0020] Figure 2 This is a scanning electron micrograph of Lactobacillus plantarum M111.
[0021] Figure 3 This is the agarose gel electrophoresis diagram of the 16S rDNA target fragment amplified from Lactobacillus plantarum M111.
[0022] Figure 4 This is the 16S rDNA phylogenetic tree of Lactobacillus plantarum M111.
[0023] Figure 5 Phylogenetic tree of rpoA of Lactobacillus plantarum M111.
[0024] Figure 6 This is a co-aggregation diagram of Lactobacillus plantarum M111 and pathogenic bacteria. DETAILED DESCRIPTION
[0025] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further explained below in combination with specific implementation methods. However, the following examples are merely examples of the present invention and do not represent the scope of protection of the rights limited by the present invention. The scope of protection of the present invention shall be subject to the claims.
[0026] In the description of the present invention, it should be noted that all terms used in the present invention (including technical terms and scientific terms) have the same meanings as those generally understood by ordinary technicians in the field to which the present invention belongs, and cannot be understood as limiting the present invention; it should be further understood that the terms used in the present invention should be understood to have the same meanings as these terms in the context of this specification and in the relevant fields, and should not be understood in an idealized or overly formal sense, unless explicitly defined in the present invention.
[0027] The present invention also provides the following embodiments:
[0028] The Lactobacillus plantarum M111 of the invention is obtained from a fresh milk sample through natural fermentation in a laboratory.
[0029] The operation example of extracting the bacteria from fresh milk of the present invention is as follows:
[0030] Example 1 Screening and Isolation of Bacteria
[0031] Take fresh milk samples and culture them at 37℃ for 3-7 days. Select naturally coagulated naturally fermented yogurt samples with yogurt flavor and dilute them by 10 -3 , 10 -4 , 10 -5 , take 100 μL and spread it in MRS medium at 37℃ for 36 to 72 hours, observe the colony morphology, select the red single colony, purify it three times, and analyze the inhibition effect of α-amylase and α-glucosidase. The strain with excellent comprehensive inhibition rate was selected and saved and named M111.
[0032] Example 2 Identification of bacterial species
[0033] 2.1 Observation of bacterial morphology
[0034] The colony morphology of M111 is as follows Figure 1 As shown, the bacterial morphology is Figure 2 As shown, the main morphological characteristics of M111 are as follows: round colonies, milky white on MRS medium, and oval-shaped bacteria that are close to circular.
[0035] 2.2 Analysis of sugar fermentation test of bacteria
[0036] According to the method of GB 4789.35-2016 "National Food Safety Standard Food Microbiology Test Lactic Acid Bacteria Test", the strain M111 was subjected to a sugar fermentation test. Different types of test sugars (esculin, maltose, mannitol, cellobiose, salicin, sucrose, raffinose, sorbitol) were added to the sugar fermentation test basal medium at a concentration of 0.5% and dissolved in small test tubes, and sterilized at 121°C for 20 minutes. The strain to be tested was inoculated at an inoculum of 2%, cultured at 37°C for 48 hours, and the color results of each test tube were observed and recorded.
[0037] According to the results in Table 1, strain M111 can ferment and utilize eight carbon sources including esculin, maltose, and mannitol.
[0038] Table 1 Sugar fermentation test results of strain M111
[0039]
[0040] Note: “+” indicates a positive result, and “-” indicates a negative result.
[0041] 2.3 Molecular biological identification of strain M111
[0042] (1) The DNA of strain M111 was extracted using the bacterial genomic DNA extraction kit produced by Tiangen Biochemical Technology (Beijing) Co., Ltd.
[0043] PCR amplification of 16S rDNA sequence: Amplify the 16S rDNA gene sequence, the primers used are
[0044] F9-27: 5'-GAGTTTGATCCTGGCTCAG-3';
[0045] R1525-1542: 5'-AGAAAGGAGGTGATCCAGCC-3'.
[0046] PCR amplification of rpoA gene sequence: The primers used were
[0047] rpoA-21-F:5'-ATGATYGARTTTGAAAAACC-3';
[0048] rpoA-22-R:5'-ACYTTVATCATNTCWGVYTC-3'.
[0049] PCR reaction system: 2×Mix 25μL, primers and DNA 2μL each, ddH2O 19μL.
[0050] PCR amplification program: pre-denaturation at 93°C for 4 min, then denaturation at 94°C for 30 s, annealing at 55°C (16S rDNA) or 50°C (rpoA) for 60 s, extension at 72°C for 90 s, for a total of 30 cycles, and finally full extension at 72°C for 10 min, and storage at 4°C.
[0051] (3) PCR product detection and sequencing analysis: Take 5 μL of PCR product and add 1% agarose gel electrophoresis containing EB to separate and test. The amplified 16S rDNA target fragment is about 1500 bp in length. The gel electrophoresis diagram is as follows: Figure 3 The product containing the target fragment was commissioned to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. After comparison with the NCBI website, it was found that the homology between strain M111 and Lactiplantibacillus plantarum and Lactiplantibacillus pentosus was more than 99%, and Figure 4The phylogenetic tree shows that strain M111 is on the same branch as Lactiplantibacillus plantarum and Lactiplantibacillus pentosus. 16S rDNA cannot distinguish them well, so we further compared the rpoA gene. After comparison on the NCBI website, strain M111 has a homology of 99.36% with Lactiplantibacillus plantarum and 97.56% with Lactiplantibacillus pentosus. Figure 5 It can be seen that strain M111 and Lactiplantibacillus plantarum are on the same branch, and combined with the previous sugar fermentation experiment, strain M111 was determined to be Lactiplantibacillus plantarum.
[0052] The results of 16S rDNA sequencing of strain M111 are as follows:
[0053] SEQ ID NO.1:
[0054] CCGGCGGGGCCTATACTGCAGTCGAACGAACTCTGGTATTGATTGGTGCTTGC
[0055] ATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACC
[0056] TGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAAC
[0057] TTGGACCGCATGGTCCGAGCTTGAAAGATGGCTTCGGCTATCACTTTTGGATGGT
[0058] CCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGCAATGATACGT
[0059] AGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACT
[0060] CCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGA
[0061] GCAACGCCGCGTGAGTGAAGAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAA
[0062] GAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAG
[0063] CCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGT
[0064] CCGGATTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAA
[0065] AGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAG
[0066] AAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGA
[0067] ACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAA
[0068] GTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAA
[0069] TGCTAAGTGTTGGAGGGTTTCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCAT
[0070] TCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGC
[0071] CCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTAC
[0072] CAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACAT
[0073] GGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAA
[0074] GTCCCGCAACGAGCGCAACCCTTATTATCAGTTGCCAGCATTAAGTTGGGCACTC
[0075] TGGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCAT
[0076] CATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTT
[0077] GCGAACTCGCGAGAGTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAG
[0078] GCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGC
[0079] CGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGT
[0080] TTGTAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAACCAGCCGCCTAAGGTGGGACAGATGATTAGGGTGAAGTCGTAACAAGGAGCTA。
[0081] The sequencing result of the rpoA sequence of strain M111 is as follows:
[0082] SEQ ID NO.2:
[0083] CCCAGGTGAAACGACAACTATGGTAAGTTTGTTGTAGAACCGCTTGAACGCGGTTATGGTACAACTTTAGGGAATTCACTTCGTCGGATTCTTCTTTCTTCTTTACCTGGCGCTGCTGTTACTAGTATTCAAATTGATGGTGTTCTTCATGAATTTTCAACGATTGAGGGCGTAACGGAAGACGTTACAGCAATTATCTTGAATGTTAAGAAGATTGCACTTAAGTTGGAATCAGACGAAACCAAGACGTTGGAAATCGACGTTAAGGGTCCTGCTAACGTTACTGCCGGTGATATCATTGGCGATGCGGACGTAGAAGTCTTGAATCCAGACTTACCAATTTGTACCGTAGCAGACGGGGCACACTTCCATATGCGTATGACCGCAAATACTGGTCGTGGTTATGTTTCCGCTGAGGATAACAAACATCGTGAAGATGACATGCCAATTGGCGTTTTAGCTGTTGATTCATTGTATTCTCCAATCGAACGTGTCAACTACCAAGTTGAAAACACGCGGGTTGGTCAACGTGATGATTTCGATAAGTTAACCTTAGACGTTTGGACAAATGGTTCAATCACTCCAAGTGAAGCCATTAGTCTATCAGCCAAAATCCTGACTGATCACCTTTCAATCTTCGTAAATCTCACTGATGAAGCTAAAAACACTGATGTGATGGTCGAGAAGGAAGAAACGCATAAGGAAAAGATGTTAGAAATGACGATTGAAGAGTTAGATCTCTCCGTCCGTTCATACAATTGCTTGAAGCGTGCTGGCATCAACAACGGTCCAAGAAATT
[0084] The present invention provides the performance characterization of Lactiplantibacillus plantarum M111 as follows:
[0085] Example 3 Analysis of the inhibitory ability of Lactiplantibacillus plantarum M111 against α-amylase and α-glucosidase.
[0086] Preparation of fermentation supernatant CFS of Lactobacillus plantarum M111: Take the bacterial liquid cultured for two generations in MRS medium at 37°C in a centrifuge tube, centrifuge at 4°C and 4500r / min for 10min, collect the supernatant and filter it through a 0.22μm water system microfiltration membrane to obtain CFS.
[0087] α-Amylase inhibition ability assay:
[0088] Add 100 μL of α-amylase solution (0.06 mg / mL) prepared with PBS (0.1 mol / L, pH 6.8) buffer to the ELISA plate, then add 100 μL of the test solution and react at 37°C for 30 min, then add 100 μL of 0.1% soluble starch solution to the system and react at 37°C for 15 min, finally add 5 μL of dilute iodine solution, and measure the OD value at 660 nm on the ELISA reader. The inhibition rate calculation formula is as follows:
[0089]
[0090] Wherein A is the sample group, containing sample solution and α-amylase solution; B is the sample blank group, containing sample solution but not α-amylase solution; C is the control group, containing no sample solution but α-amylase solution; D is the blank group, containing no sample solution and no α-amylase solution.
[0091] α-Glucosidase inhibition ability assay:
[0092] Add 50 μL of PBS (0.1 mol / L, pH 6.8) buffer to the ELISA plate, then add 10 μL of α-glucosidase solution (0.8 U / mL), add 50 μL of the test solution and react at 37°C for 15 min, then add 50 μL of PNPG solution (1 mg / mL) and react at 37°C for 30 min, finally add 80 μL of Na2CO3 solution (0.2 mol / L) to terminate the reaction, and measure the OD value at 405 nm with an ELISA reader. The inhibition rate is calculated as follows:
[0093]
[0094] Wherein A is the sample group, containing sample solution and α-glucosidase solution; B is the sample blank group, containing sample solution but not α-glucosidase solution; C is the control group, containing no sample solution but α-glucosidase solution; D is the blank group, containing no sample solution and no α-glucosidase solution.
[0095] Table 2 Inhibitory effect of fermentation supernatant of Lactobacillus plantarum M111 on α-glucosidase
[0096]
[0097] The results of the inhibition ability of the fermentation supernatant of Lactobacillus plantarum M111 on α-amylase and α-glucosidase are shown in Table 2. It can be seen that the fermentation supernatant of Lactobacillus plantarum M111 has a good inhibitory effect on α-amylase and α-glucosidase, and the inhibition rates are 71.44% and 62.14%, respectively.
[0098] Example 4 Tolerance analysis of Lactobacillus plantarum M111 in simulated artificial gastric fluid environment
[0099] Take the plant lactobacillus M111 fermented for 24~48h, 4500r / min centrifugal 10min collects bacterial body, adds physiological saline (0.85%) of same volume and mixes for standby use; Prepare artificial gastric juice (125mM NaCl, 7mM KCl, 45mM NaHCO3 and 3g / Lpepsin), adjust pH value to 2.0, 2.5, 3.0, standby use after filtering through 0.22μm microporous filter membrane, take 1mL of the bacterial liquid of processing in the artificial gastric juice of different pH value of 9mL, place 37 ℃ of constant temperature culture, sample at 1h, 2h, 3h, 4h, 5h time of cultivation, take 0.9mL dilution at each time, add 0.1mL of PI diluent, dye for 10min at 37 ℃, flow cytometer detects total bacterial particle number P1 and dead particle number P2, plant lactobacillus M111 survival rate / %=(P1-P2) / P1. Experimental result is as shown in Table 3.
[0100] Table 3 Survival rate of Lactobacillus plantarum M111 in simulated artificial gastric fluid environment (%)
[0101]
[0102] It can be clearly seen from Table 3 that Lactobacillus plantarum M111 has extremely high tolerance to simulated artificial gastric juice of pH 3.0 and pH 2.5, and its tolerance to pH 3.0 and pH 2.5 in the initial 1h reaches 99.32% and 98.53%, respectively, and after 5h of cultivation, its tolerance still reaches 98.34% and 97.42%, indicating that Lactobacillus plantarum M111 can tolerate the simulated artificial gastric juice environment of pH 3.0 and pH 2.5 very well; at the same time, in the simulated artificial gastric juice environment of pH 2.0, its survival rate is still over 50% after culturing for 5h, reaching 58.67%, which shows that Lactobacillus plantarum M111 also has a certain tolerance to the simulated artificial gastric juice of pH 2.0.
[0103] Example 5 Tolerance analysis of Lactobacillus plantarum M111 in a simulated artificial pancreatic juice environment
[0104] Take the plant lactobacillus M111 fermented for 24-48h, centrifuge for 5min at 8000r / min to collect the cells, add the physiological saline (0.85%) of the same volume to mix for standby use; prepare protein pancreatic juice (0.1% pancreatin w / v, 0.15% ox bile), adjust the pH value to 7.5 and 8.0 respectively, filter through 0.22μm microporous membrane for standby use, take 1mL of the processed bacterial liquid in 9mL of the protein pancreatic juice of different pH values, place 37℃ constant temperature culture, sample at 3h and 6h, take 0.9mL dilution at each time, add PI 0.1ml, dye at 37℃ for 10min, flow cytometer detects the total bacterial particle number P1 and the number of dead particles P2, and the survival rate / % of plant lactobacillus M111 is equal to (P1-P2) / P1. The experimental results are shown in Table 4.
[0105] Table 4 Survival rate of Lactobacillus plantarum M111 in simulated artificial pancreatic juice environment (%)
[0106]
[0107] As can be seen from Table 4, Lactobacillus plantarum has good tolerance in the environments of simulated artificial pancreatic juice pH 7.5 and pH 8.0, and the survival rates after 3 hours of culture are 97.85% and 97.45%, respectively; after 6 hours of culture, they still reach 96.80% and 95.80%, both exceeding 95%, indicating that Lactobacillus plantarum M111 has extremely high tolerance to simulated artificial pancreatic juice.
[0108] Example 6 Inhibitory effect of Lactobacillus plantarum M111 on five pathogenic bacteria including Escherichia coli and Staphylococcus aureus
[0109] (1) Activation of pathogenic bacteria
[0110] Take out the cryopreservation tubes containing five pathogenic bacteria, namely, Streptococcus mutans, Staphylococcus aureus, Escherichia coli, Candida albicans, and Shigella sonnei, from the -80°C ultra-low temperature freezer, inoculate Streptococcus mutans into BHI liquid medium, Candida albicans into YPD liquid medium, Staphylococcus aureus, Escherichia coli, and Shigella sonnei into LB liquid medium. After culturing the above five pathogenic bacteria at 37°C for two generations, centrifuge at 4500r / min for 10min, discard the supernatant, collect the bacteria, resuspend them with PBS (0.1mol / L, pH 6.8) buffer, and adjust the bacterial solution concentration to OD 600nm =0.5.
[0111] (2) Inhibition zone determination
[0112] 100 μL of Streptococcus mutans suspension was applied to BHI solid medium, 100 μL of Candida albicans suspension was applied to YPD solid medium, and 100 μL of Staphylococcus aureus, Escherichia coli and Shigella sonnei suspension was applied to LB solid medium. The Oxford cup method was adopted, and an Oxford cup was placed in each culture medium, and 200 μL of Lactobacillus plantarum M111 bacterial solution after two generations of culture was poured into the Oxford cup. After culturing at 37°C for 24 hours, the diameter of the inhibition zone was measured with a vernier caliper. The experimental results are shown in Table 5.
[0113] Table 5 Antibacterial ability of Lactobacillus plantarum M111
[0114]
[0115] Note: “+++” means the diameter of the inhibition zone is ≥16mm; “++” means the diameter of the inhibition zone is between 14 and 16mm; “+” means the diameter of the inhibition zone is ≤14mm; “-” means no antibacterial effect.
[0116] As can be seen from Table 5, Lactobacillus plantarum M111 has an antibacterial effect on 5 common pathogens. Among them, the antibacterial intensity against Streptococcus mutans is the strongest, and the diameter of the inhibition zone exceeds 20mm, reaching 20.29mm; the antibacterial intensity against Shigella sonnei is second, and the diameter of the inhibition zone reaches 17.95mm; the antibacterial intensity against Escherichia coli is relatively the smallest, and its antibacterial zone diameter is 13.42mm.
[0117] Example 7 Analysis of the coaggregation of Lactobacillus plantarum M111 against five pathogenic bacteria including Escherichia coli and Staphylococcus aureus
[0118] The pathogenic bacteria suspension was prepared according to the method in Example 6. Meanwhile, the Lactobacillus plantarum M111 cultured for two generations was centrifuged at 4500 r / min for 10 min, the supernatant was discarded and the bacteria were collected and resuspended in PBS (0.1 mol / L, pH 6.8) buffer to adjust the bacterial suspension concentration to OD 600nm =0.5. The bacterial suspension of Lactobacillus plantarum M111 was mixed with the bacterial suspensions of five indicator bacteria in equal volumes, and the initial OD value of the mixed bacterial suspension at 0 h was measured. 600nm The value was recorded as A0, and the mixed bacterial solution was incubated at 37℃ for 2h, 4h, and 24h, and the upper bacterial solution was carefully aspirated to determine its OD 600nm The value is recorded as A t The coaggregation calculation formula is as follows:
[0119]
[0120] Where A t is the OD value of static th; A0 is the initial OD value of the mixed bacterial solution at 0h. Figure 6 shown.
[0121] from Figure 6 It can be seen that after 2 hours of co-culture, the co-aggregation rate of Lactobacillus plantarum M111 to 5 pathogens is between 2% and 34.22%, among which the co-aggregation rate to Candida albicans is the highest, reaching 34.22%, which is significantly higher (P<0.05) than the other pathogenic strains, followed by Streptococcus mutans, with a co-aggregation rate of 7.33%. The co-aggregation effect on Escherichia coli is the worst, with only 2% co-aggregation rate after 2 hours of co-culture. After 4 hours of co-culture, the co-aggregation rate of Lactobacillus plantarum M111 to Streptococcus mutans and Shigella sonnei increased significantly, reaching 20.83% and 19.76% respectively, but the co-aggregation rate to Candida albicans is still the highest, reaching 45.80%. After 24 hours of co-culture, the co-aggregation rates of Lactobacillus plantarum M111 to the five pathogens exceeded 40%, among which the co-aggregation rates to Candida albicans and Streptococcus mutans were the highest, reaching 74.74% and 71.75% respectively, and the co-aggregation rate to Escherichia coli was relatively the smallest, at 44.85%.
[0122] Example 8 Analysis of the sensitivity test of Lactobacillus plantarum M111 to antibiotics
[0123] After two generations of culture, Lactobacillus plantarum M111 was centrifuged at 4500 r / min for 10 min, and the supernatant was discarded. After resuspending with PBS (0.1 mol / L, pH 6.8) buffer, the bacterial solution concentration was adjusted to 10 8 CFU / mL(OD 600nm =1.0). 100 μL of bacterial suspension was applied to MRS solid medium, and an antibiotic sensitive paper was placed on each medium with tweezers using the filter paper method, and cultured at 37°C for 24 hours. The diameter of the inhibition zone was measured with a vernier caliper, and the drug resistance was determined according to the standards revised by the Clinical and Laboratory Standards Institute (CLSI). The test results are shown in Table 6.
[0124] Table 6 Results of sensitivity test of Lactobacillus plantarum M111 to 20 antibiotics
[0125]
[0126]
[0127] Note: S (sensitive); I (intermediately sensitive); R (resistant)
[0128] As can be seen from Table 6, among the 20 antibiotics tested, Lactobacillus plantarum M111 showed sensitivity to 14 antibiotics such as neomycin, medcamycin, and amikacin, among which carbenicillin was the most sensitive, with an inhibition zone diameter of 35.70 mm, followed by medcamycin, with an inhibition zone diameter of 34.64 mm, and 5 types of antibiotics with inhibition zone diameters exceeding 30 mm. It was moderately sensitive to kanamycin, with an inhibition zone diameter of 15.25 mm. Lactobacillus plantarum M111 showed resistance to 5 antibiotics such as ofloxacin, ciprofloxacin, and polymyxin B. In general, Lactobacillus plantarum M111 showed a certain degree of sensitivity to most of the antibiotics tested.
[0129] Example 9 Preparation of probiotic preparations using Lactobacillus plantarum M111
[0130] The Lactobacillus plantarum M111 is inoculated into a culture medium, such as an MRS culture medium, and cultured at 37°C for more than 15 hours. The bacterial cells are collected by centrifugation and resuspended in, for example, physiological saline or PBS buffer to prepare a liquid bacterial preparation containing Lactobacillus plantarum M111.
[0131] Optionally, the bacterial cells of Lactobacillus plantarum M111 are resuspended in a cell protectant and a carrier, and freeze-dried to obtain a solid bacterial powder preparation containing Lactobacillus plantarum M111.
[0132] Optionally, the Lactobacillus plantarum M111 liquid or solid preparation is mixed with a weight-loss food commonly used in food or health food to prepare different types of food, health food or medicine.
[0133] Example 10 Preparation of fermented food by Lactobacillus plantarum M111
[0134] The method comprises the following steps: preparing a fermented Lactobacillus plantarum M111 yeast solution, taking various fruits, Chinese herbal medicines and cereals as raw materials and various sugars as auxiliary materials, inoculating the Lactobacillus plantarum M111, fermenting the mixture under certain temperature conditions (such as 37° C.) for a certain period of time, preparing a fermented product, inactivating or not inactivating the fermented product, and adding common beverage auxiliary materials to the original solution or diluting the mixture in different proportions to prepare a fermented food.
[0135] According to the results of the above examples, the Lactobacillus plantarum M111 provided by the present invention has the following properties and effects:
[0136] a. Able to utilize carbon sources such as cellobiose, salicin, and sucrose.
[0137] b. After being retained in a simulated artificial gastric juice environment of pH 2.0-3.0 for 5 hours, the survival rate was still over 50%, and after being retained in a simulated artificial pancreatic juice environment of pH 7.5-8.0 for 6 hours, the survival rate was over 95%.
[0138] c. The fermentation supernatant of Lactobacillus plantarum M111 had an inhibition rate of 71.44% on α-amylase and 62.14% on α-glucosidase.
[0139] d. Lactobacillus plantarum M111 has a good inhibitory effect on Escherichia coli, Staphylococcus aureus, Candida albicans, Shigella sonnei, and Streptococcus mutans.
[0140] e. Lactobacillus plantarum M111 is sensitive to 14 common antibiotics.
[0141] f. Lactobacillus plantarum M111 is obtained from daily fresh milk through natural fermentation. It is highly safe for consumption and can be developed as a blood sugar-lowering food and an antibacterial food, with broad application prospects.
[0142] Unless otherwise specified, the experimental operation methods involved in the embodiments of the present invention are conventional experimental operation methods in the art, and the reagents or instruments involved can be purchased from regular channels.
[0143] In addition, those skilled in the art should understand that, although there are many problems in the prior art, each embodiment or technical solution of the present invention can be improved in only one or several aspects, without having to solve all the technical problems listed in the prior art or background technology at the same time. Those skilled in the art should understand that the content not mentioned in a claim should not be used as a limitation on the claim.
[0144] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A strain of Lactobacillus plantarum, characterized in that: The strain is Lactiplantibacillus plantarum M111, which was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on May 15, 2024, with the deposit number CGMCC NO.30629.
2. The use of the plant lactobacillus strain in inhibiting foodborne pathogens as claimed in claim 1, characterized in that: The foodborne pathogens include Escherichia coli, Staphylococcus aureus, Candida albicans, Streptococcus mutans, and Shigella sonnei.
3. The use of the plant lactobacillus strain in inhibiting α-glucosidase as claimed in claim 1, characterized in that: The α-glycosidase includes α-amylase and α-glucosidase.
4. A composition containing the live strain of Lactobacillus plantarum M111 as claimed in claim 1, characterized in that The number of Lactobacillus plantarum M111 is ≥ 1×10 6 CFU / mL or ≥1×10 6 CFU / g, the composition includes a microbial preparation, a food, a health product or a medicine.
5. Use of the Lactobacillus plantarum M111 according to claim 1 or the composition according to claim 4 in the preparation of fermented food.
Citation Information
Patent Citations
Lactobacillus plantarum ZDY2013 with high acid resistance
CN105255752A
Caries resistant lactobacillus plantarum K41 and application thereof
CN108486022A
Method capable of inhibiting streptococcus mutans and candida albicans double-bacteria biofilm
CN109908185A
Preparation and application of probiotics beneficial to female genital tract health
CN115137758A
Multifunctional plant lactobacillus and application thereof
CN116478888A
